GordonMD Global Investments

GordonMD Global Investments is a private investment firm founded in 2021 by Dr. Craig Gordon, a licensed physician with over 13 years of experience managing global biopharmaceutical portfolios. The firm focuses on identifying differentiated investment opportunities in biopharmaceutical companies primarily located in the United States, Europe, and Japan. It currently provides investment management and administrative services to a hedge fund investing primarily in publicly traded companies as well as to two private equity funds.

The firm's investment strategy encompasses various stages, including early stage, growth, late stage, pre-IPO, and buyout, with a focus on private equity and venture capital investments. Its portfolio spans multiple industries, notably biotechnology, pharmaceutical, healthcare, and finance. Notable portfolio companies include Radionetics Oncology, a clinical-stage pharmaceutical company specializing in radiopharmaceuticals for cancer treatment, and Star Therapeutics, a clinical-stage biotechnology company developing novel antibodies for bleeding disorders.

GordonMD Global Investments emphasizes collaboration and innovation, as evidenced by its strategic agreements with partners like Eli Lilly and Company and Partners Investment Co., Ltd. These collaborations aim to advance the development of breakthrough therapies and expand the firm's global reach in the biopharmaceutical sector. The firm's commitment to fostering innovation is further demonstrated by its support for Radionetics Oncology's strategic agreement with Eli Lilly, which received a $140 million upfront cash payment and the potential for a $1 billion acquisition.